GERN
Geron Corporation [GERN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
GERN Stock Summary
Top 10 Correlated ETFs
GERN
Top 10 Correlated Stocks
GERN
In the News
GERN Financial details
Company Rating
Neutral
Market Cap
2.14B
Income
-184.08M
Revenue
237K
Book val./share
0.42
Cash/share
0.56
Dividend
-
Dividend %
-
Employees
141
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-11.77
Forward P/E
-
PEG
9.57
P/S
9031.79
P/B
8.73
P/C
6.4
P/FCF
-12.75
Quick Ratio
3.11
Current Ratio
3.16
Debt / Equity
0.33
LT Debt / Equity
0.14
-
-
EPS (TTM)
-0.32
EPS next Y
-
EPS next Q
-
EPS this Y
-13.51%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-0.61%
Revenue last 5Y
-12.42%
Revenue Q/Q
-85.98%
EPS Q/Q
13.07%
-
-
-
-
SMA20
33.33%
SMA50
100%
SMA100
100%
Inst Own
43.36%
Inst Trans
0.69%
ROA
-47%
ROE
-63%
ROC
-0.68%
Gross Margin
-12640%
Oper. Margin
-81833%
Profit Margin
-77671%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.64-4.05
52W High
-10.38%
52W Low
+258.5%
RSI
62
Rel Volume
0.38
Avg Volume
12.2M
Volume
4.6M
Perf Week
-4.91%
Perf Month
70.71%
Perf Quarter
96.98%
Perf Half Y
93.78%
-
-
-
-
Beta
0.608
-
-
Volatility
0.09%, 0.51%
Prev Close
-3.89%
Price
3.585
Change
-3.37%
GERN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.33 | -0.28 | -0.37 | -0.37 | -0.32 | |
| Operating cash flow per share | -0.23 | -0.25 | -0.29 | -0.33 | -0.29 | |
| Free cash flow per share | -0.23 | -0.25 | -0.29 | -0.34 | -0.29 | |
| Cash per share | 0.73 | 0.72 | 0.56 | 0.45 | 0.59 | |
| Book value per share | 0.71 | 0.78 | 0.39 | 0.21 | 0.43 | |
| Tangible book value per share | 0.71 | 0.78 | 0.39 | 0.21 | 0.43 | |
| Share holders equity per share | 0.71 | 0.78 | 0.39 | 0.21 | 0.43 | |
| Interest debt per share | 0.01 | 0.11 | 0.18 | 0.16 | 0.16 | |
| Market cap | 258.62M | 431.62M | 399.71M | 921.5M | 1.2B | |
| Enterprise value | 247.26M | 451.05M | 419.84M | 920.04M | 1.22B | |
| P/E ratio | -4.07 | -5.71 | -3.3 | -6.53 | -6.54 | |
| Price to sales ratio | 562.21 | 1.71K | 286.94 | 1.55K | 5.08K | |
| POCF ratio | -5.9 | -6.48 | -4.18 | -7.23 | -7.21 | |
| PFCF ratio | -5.85 | -6.44 | -4.17 | -7.21 | -7.17 | |
| P/B Ratio | 1.91 | 2.05 | 3.16 | 11.52 | 4.86 | |
| PTB ratio | 1.91 | 2.05 | 3.16 | 11.52 | 4.86 | |
| EV to sales | 537.52 | 1.78K | 301.39 | 1.54K | 5.14K | |
| Enterprise value over EBITDA | -3.41 | -6.02 | -3.76 | -6.81 | -6.32 | |
| EV to operating cash flow | -5.64 | -6.77 | -4.39 | -7.22 | -7.29 | |
| EV to free cash flow | -5.59 | -6.73 | -4.38 | -7.2 | -7.26 | |
| Earnings yield | -0.25 | -0.18 | -0.3 | -0.15 | -0.15 | |
| Free cash flow yield | -0.17 | -0.16 | -0.24 | -0.14 | -0.14 | |
| Debt to equity | 0.02 | 0.14 | 0.44 | 0.7 | 0.33 | |
| Debt to assets | 0.02 | 0.11 | 0.24 | 0.29 | 0.21 | |
| Net debt to EBITDA | 0.16 | -0.26 | -0.18 | 0.01 | -0.08 | |
| Current ratio | 5.03 | 6.46 | 4.11 | 2.35 | 3.16 | |
| Interest coverage | 0 | -101.2 | -30.48 | -20.13 | -23.33 | |
| Income quality | 0.64 | 0.88 | 0.82 | 0.9 | 0.91 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 45.42 | 101.49 | 21.3 | 73.2 | 291.71 | |
| Research and developement to revenue | 113.2 | 203.51 | 61.54 | 160.27 | 527.62 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0.01 | 0 | 0 | 0 | |
| Capex to revenue | -0.9 | -1.58 | -0.15 | -0.72 | -3.5 | |
| Capex to depreciation | -0.53 | -0.43 | -0.26 | -0.5 | -0.8 | |
| Stock based compensation to revenue | 13.22 | 27.25 | 5.8 | 13.42 | 78.17 | |
| Graham number | 2.31 | 2.21 | 1.79 | 1.32 | 1.78 | |
| ROIC | -0.48 | -0.31 | -0.64 | -0.98 | -0.58 | |
| Return on tangible assets | -0.38 | -0.28 | -0.54 | -0.74 | -0.47 | |
| Graham Net | 0.58 | 0.5 | 0.26 | 0.17 | 0.33 | |
| Working capital | 113.45M | 168.92M | 141.69M | 103.55M | 233.28M | |
| Tangible asset value | 135.16M | 210.95M | 126.42M | 80M | 247.95M | |
| Net current asset value | 111.25M | 140.08M | 87.59M | 69.67M | 195.22M | |
| Invested capital | 0.02 | 0.14 | 0.44 | 0.7 | 0.33 | |
| Average receivables | 985K | 762K | 1.24M | 2.45M | 2.4M | |
| Average payables | 1.08M | 4.05M | 6.8M | 8.44M | 8.18M | |
| Average inventory | -985K | -762K | -1.06M | -2.27M | -1.57M | |
| Days sales outstanding | 636.37 | 1.04K | 461.95 | 1.93K | 2.55K | |
| Days payables outstanding | 8.41 | 50.46 | 3.12K | 4.28K | 2.18K | |
| Days of inventory on hand | -5.71 | -5.27 | -652.15 | -1.32K | 0 | |
| Receivables turnover | 0.57 | 0.35 | 0.79 | 0.19 | 0.14 | |
| Payables turnover | 43.41 | 7.23 | 0.12 | 0.09 | 0.17 | |
| Inventory turnover | -63.93 | -69.32 | -0.56 | -0.28 | 0 | |
| ROE | -0.47 | -0.36 | -0.96 | -1.76 | -0.74 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.1 | -0.07 | -0.09 | -0.08 | -0.09 | |
| Operating cash flow per share | -0.09 | -0.09 | -0.05 | -0.09 | -0.07 | |
| Free cash flow per share | -0.09 | -0.09 | -0.05 | -0.09 | -0.07 | |
| Cash per share | 0.42 | 0.7 | 0.68 | 0.54 | 0.56 | |
| Book value per share | 0.2 | 0.6 | 0.55 | 0.5 | 0.42 | |
| Tangible book value per share | 0.2 | 0.6 | 0.55 | 0.5 | 0.42 | |
| Share holders equity per share | 0.2 | 0.6 | 0.55 | 0.5 | 0.42 | |
| Interest debt per share | 0.14 | 0.11 | 0.11 | 0.09 | 0.14 | |
| Market cap | 987.71M | 1.18B | 1.76B | 1.23B | 1.26B | |
| Enterprise value | 986.25M | 1.12B | 1.76B | 1.25B | 1.27B | |
| P/E ratio | -5.82 | -7.76 | -8.92 | -6.86 | -6.04 | |
| Price to sales ratio | 9.59K | 56.26K | 60.58K | 7.49K | 54.58K | |
| POCF ratio | -28.08 | -25.48 | -59.35 | -24.17 | -31.15 | |
| PFCF ratio | -27.96 | -25.28 | -58.95 | -24.07 | -31.1 | |
| P/B Ratio | 12.35 | 3.62 | 5.89 | 4.23 | 5.06 | |
| PTB ratio | 12.35 | 3.62 | 5.89 | 4.23 | 5.06 | |
| EV to sales | 9.58K | 53.53K | 60.54K | 7.65K | 55.22K | |
| Enterprise value over EBITDA | -24.27 | -31.05 | -37.4 | -26.34 | -23.5 | |
| EV to operating cash flow | -28.03 | -24.25 | -59.32 | -24.66 | -31.52 | |
| EV to free cash flow | -27.92 | -24.05 | -58.91 | -24.57 | -31.47 | |
| Earnings yield | -0.04 | -0.03 | -0.03 | -0.04 | -0.04 | |
| Free cash flow yield | -0.04 | -0.04 | -0.02 | -0.04 | -0.03 | |
| Debt to equity | 0.7 | 0.17 | 0.19 | 0.19 | 0.33 | |
| Debt to assets | 0.29 | 0.13 | 0.13 | 0.14 | 0.21 | |
| Net debt to EBITDA | 0.04 | 1.58 | 0.02 | -0.53 | -0.27 | |
| Current ratio | 2.35 | 8.81 | 5.2 | 3.75 | 3.16 | |
| Interest coverage | -20.92 | -20.86 | -25.94 | 23.05 | -23.39 | |
| Income quality | 0.83 | 1.22 | 0.6 | 1.13 | 0.78 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 134.41 | 614 | 568.62 | 111.89 | 930.48 | |
| Research and developement to revenue | 273.88 | 1.3K | 1.22K | 179.43 | 1.43K | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0.01 | 0.01 | 0 | 0 | |
| Capex to revenue | -1.36 | -17.71 | -6.97 | -1.17 | -2.78 | |
| Capex to depreciation | -0.61 | -1.48 | -0.73 | -0.72 | -0.27 | |
| Stock based compensation to revenue | 21.24 | 141 | 136.03 | 43.93 | 192 | |
| Graham number | 0.68 | 0.97 | 1.05 | 0.93 | 0.91 | |
| ROIC | -0.3 | -0.1 | -0.15 | -0.13 | -0.16 | |
| Return on tangible assets | -0.22 | -0.09 | -0.12 | -0.11 | -0.13 | |
| Graham Net | 0.16 | 0.52 | 0.47 | 0.35 | 0.32 | |
| Working capital | 103.55M | 343.11M | 304.71M | 245.7M | 233.28M | |
| Tangible asset value | 80M | 326.06M | 298.43M | 290.61M | 247.95M | |
| Net current asset value | 69.67M | 288.2M | 260.41M | 212.68M | 195.22M | |
| Invested capital | 0.7 | 0.17 | 0.19 | 0.19 | 0.33 | |
| Average receivables | 12.68M | 2.37M | 1.39M | 7.97M | 8.2M | |
| Average payables | 9.19M | 6.79M | 5.53M | 10.68M | 9.92M | |
| Average inventory | -12.68M | -2.37M | -530.5K | 535.5K | 268K | |
| Days sales outstanding | 2.75K | 6.84K | 3.68K | 8.1K | 6.48K | |
| Days payables outstanding | 4K | 1.21K | 2.51K | 41.85 | 2.3K | |
| Days of inventory on hand | -1.24K | -572.27 | 175.09 | 1.64 | 0 | |
| Receivables turnover | 0.03 | 0.01 | 0.02 | 0.01 | 0.01 | |
| Payables turnover | 0.02 | 0.07 | 0.04 | 2.15 | 0.04 | |
| Inventory turnover | -0.07 | -0.16 | 0.51 | 54.9 | 0 | |
| ROE | -0.53 | -0.12 | -0.16 | -0.15 | -0.21 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
GERN Frequently Asked Questions
What is Geron Corporation stock symbol ?
Geron Corporation is a US stock , located in Foster city of Ca and trading under the symbol GERN
What is Geron Corporation stock quote today ?
Geron Corporation stock price is $3.585 today.
Is Geron Corporation stock public?
Yes, Geron Corporation is a publicly traded company.
Company Profile
- Volume Average 12.2M
- Market Capitalization 2.14B
- Employee 141
- CEO Dr. John A. Scarlett M.D.
- Headquarters Foster City,CA,US
- IPO Date 1996-07-31
-
Website
https://www.geron.com 
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
